UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including
area code: (
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) |
Name of each exchange on which registered | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b)). | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c)). |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01 Other Events.
As previously disclosed by Current Reports on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on December 1, 2021, May 27, 2022, and November 23, 2022, Idera Pharmaceuticals, Inc. (the “Company”) received deficiency letters from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”), notifying the Company that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company to maintain a minimum closing bid price of $1.00 per share for continued listing on The Nasdaq Capital Market. In response to the Staff’s letter, in November 2022, the Company timely requested a hearing before a Nasdaq Hearing Panel (the “Panel”), which was held on January 5, 2023.
As also previously disclosed, the Company will be holding a special meeting of stockholders on January 12, 2023, which, subject to stockholder approval, will result in the conversion of the Company’s outstanding Series Z Preferred Stock into common stock. The Company is also asking its stockholders to approve a reverse stock split in a ratio between 17-1 to 23-1 at the special meeting. As a “change of control” will occur upon the conversion of the Series Z Preferred Stock into common shares (as that term is defined by Nasdaq), the Company will be required to meet all criteria for initial listing on The Nasdaq Capital Market at that time.
By decision dated January 10, 2023, the Panel granted the Company an extension until January 20, 2023, to complete the shareholder meeting and attendant transactions, including a reverse stock split, and thereby evidence compliance with all applicable criteria for initial listing on The Nasdaq Capital Market, including the $4.00 bid price requirement. The Company anticipates being able to satisfy the terms of the Panel’s decision prior to January 20, 2023.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IDERA PHARMACEUTICALS, INC. |
By: | /s/ Bryant D. Lim | |
Bryant D. Lim | ||
Chief Business Officer and General Counsel |
Dated: January 11, 2023
Cover |
Jan. 10, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jan. 10, 2023 |
Entity File Number | 001-31918 |
Entity Registrant Name | Idera Pharmaceuticals, Inc. |
Entity Central Index Key | 0000861838 |
Entity Tax Identification Number | 04-3072298 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 505 Eagleview Blvd. |
Entity Address, Address Line Two | Suite 212 |
Entity Address, City or Town | Exton |
Entity Address, State or Province | PA |
Entity Address, Postal Zip Code | 19341 |
City Area Code | 484 |
Local Phone Number | 348-1600 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.001 per share |
Trading Symbol | IDRA |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
JZVLA6N0VUDE,;!J=Z"XO;\'*^MPJM5&R*@^T[CF=(BA51L&Q7W^
M/=I4&0M&\Y?(3M\ -8?20$3;8T.P6BP^
M0"X99K>]9!:G
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
&UL4$L! A0#% @ RD,K5@ R,)"F$P :64 !$ M ( !*18 '1M,C,S,#,Y9#%?.&LN:'1M4$L%!@ $ 0 ! $ ' /XI $! end